Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 17/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 15/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15028921 | 0.82 | MGLL (0.40) | TLR8TLR7TLR9 | |
| SCHEMBL27358327 | 0.79 | TLR8 (0.37) | TLR8TLR7TLR9SLC18A3DRD2 | |
| SCHEMBL13499049 | 0.79 | APP (0.41) | — | |
| SCHEMBL29611795 | 0.78 | ESR2 (0.44) | TLR8TLR7TLR9 | |
| SCHEMBL26923110 | 0.78 | ESR2 (0.44) | TLR8TLR7TLR9 | |
| SCHEMBL25556114 | 0.77 | TLR8 (0.47) | TLR8TLR7TLR9SLC18A3DRD2 | |
| SCHEMBL21872033 | 0.77 | APP (0.43) | — | |
| SCHEMBL21872092 | 0.77 | APP (0.43) | — | |
| SCHEMBL21872202 | 0.77 | APP (0.43) | — | |
| SCHEMBL27358331 | 0.76 | DRD2 (0.49) | TLR8TLR7TLR9SLC18A3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | HDAC6, HDAC9, HDAC7 | TLR8 720/4885TLR7 387/4885TLR9 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.